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Abstract
The Peristeen transanal irrigation system is intended to allow people with bowel dysfunction to flush out the lower part of 
the bowel as part of their bowel management strategy. Peristeen was the subject of an evaluation by the National Institute 
for Health and Care Excellence, through its Medical Technologies Evaluation Programme, for the management of bowel 
dysfunction. The company, Coloplast, submitted a case for adoption of the technology, claiming that the technology improves 
the severity of chronic constipation or faecal incontinence and improves quality of life for people with bowel dysfunction. 
Other claimed benefits included reduced frequency of UTIs, stoma surgery and hospitalisation rates, as well as reduced 
costs. The submission was critiqued by Cedar. The clinical evidence assessed included one randomised controlled trial, and 
12 observational studies for adults and 11 studies for children. Although there are limitations in the evidence, the assessed 
studies show some improvement in outcomes for patients who choose to continue using Peristeen. The committee heard from 
patient experts that Peristeen had improved their lives and allowed them increased independence. The submitted economic 
evidence had numerous flaws, however following Cedar’s changes to the model, and additional sensitivity analysis, the use 
of Peristeen was judged unlikely to be cost incurring compared with standard bowel care. The Peristeen transanal irrigation 
system received a positive recommendation in Medical Technologies Guidance 36.
Key Points for Decision Makers 
Peristeen is used by a wide range of people with bowel 
dysfunction from different causes.
Not all patients find Peristeen acceptable or useful; how‑
ever, for those who do, it can be a significant improve‑
ment in their quality of life and can promote dignity and 
independence.
Peristeen can be difficult to use and people may require 
time, training and support to get comfortable with using 
it. Some people will choose to stop using Peristeen.
There are considerable uncertainties in the economic 
evaluation; however, on average, Peristeen is unlikely to 
cost more than standard bowel care over a relevant time 
horizon.
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1 Introduction
The National Institute for Health and Care Excellence 
(NICE) produces guidance on new or innovative medical 
devices or diagnostics—Medical Technologies Guidance 
(MTG). The aim of the guidance is to support the adoption 
of clinically effective and cost‑saving technologies in the 
UK National Health Service (NHS). The process for pro‑
ducing MTG has been previously described in detail [1].
This paper summarises Cedar’s assessment report and 
how it was used to inform the NICE MTG on the Peristeen 
transanal irrigation system to manage bowel dysfunction 
(MTG36). Cedar is a NHS–academic health care technol‑
ogy research collaboration based in Cardiff. This paper is 
part of a series that provides an insight into the develop‑
ment of NICE MTG [1].
2  Background to the Condition 
and Technology
Neurogenic bowel dysfunction can be caused by neuro‑
logical conditions such as spinal cord injury, spina bifida, 
multiple sclerosis, Parkinson’s disease and other condi‑
tions associated with impairment or loss of sphincter con‑
trol and bowel mobility disorders. Bowel dysfunction can 
also have numerous other causes, such as injury to the 
rectum or bowel, or slow transit constipation. Symptoms 
include faecal incontinence and constipation, along with 
an increased rate of urinary tract infections (UTIs).
Transanal irrigation can be used by people with bowel 
dysfunction to empty the rectum and some of the colon at 
a time and frequency that is suitable to them, and to avoid 
faecal incontinence and constipation.
Peristeen is a transanal irrigation system consisting of a 
rectal catheter with an inflatable balloon, a manual control 
unit with a pump, leg straps, and a bag to hold water. The 
constant flow pump means that the system does not depend 
on gravity, and the bag does not need to be elevated. A new 
catheter is required for every use. The manufacturer rec‑
ommends use every other day, although users will develop 
their own preference for how frequently to use the irriga‑
tion system. Peristeen received a CE mark in May 2003 as 
a class 1 medical device.
A variety of systems, including Peristeen, are available 
that differ in design and use. These choices should be dis‑
cussed by clinician and patient, and a number of systems 
may be tried before a preferred device for transanal irriga‑
tion is found for that particular patient.
Currently, alternative treatment options include medi‑
cation (oral drugs, suppositories and enemas), changes 
to diet, and physiotherapy. People with bowel dysfunc‑
tion may also manage their symptoms using biofeedback, 
bowel washouts and manual removal of faeces. Some 
patients may need or may prefer surgery, i.e. a colostomy, 
ileostomy, sacral nerve stimulation or an antegrade conti‑
nence enema procedure.
The benefits claimed by the company to people with 
bowel dysfunction are that use of Peristeen improves symp‑
toms/reduces the severity of chronic constipation; reduces 
the severity and frequency of faecal incontinence; improves 
quality of life for people with bowel dysfunction; and 
reduces the incidence of UTIs in people with neurogenic 
bowel dysfunction.
The benefits claimed by the company to the healthcare 
system are that the use of Peristeen reduces the rate of 
stoma surgery in people with neurogenic bowel dysfunction; 
reduces the frequency, and therefore the treatment costs, of 
UTIs; reduces the cost of treating neurogenic bowel dysfunc‑
tion in people who have experienced unsuccessful standard 
bowel care as first‑line treatment; and reduces the rate of 
hospitalisation in people with neurogenic bowel dysfunction.
3  Decision Problem (Scope)
In their evidence submission, the manufacturer must keep 
within the scope of the evaluation. The scope is defined by 
NICE in the form of a PICO table (population, intervention, 
comparator, outcomes, plus cost analysis and subgroups to 
be considered).
3.1  Population
The population was defined as people with bowel dysfunc‑
tion in any setting. Although the company claims were based 
on neurogenic bowel disorder, following consultation NICE 
broadened the scope to include all bowel dysfunction. Cedar 
identified that the company had inappropriately excluded 
most studies on children, and included such studies in their 
report.
3.2  Intervention
The intervention was defined as the Peristeen transanal irri‑
gation system.
3.3  Comparator
The comparator was defined as conservative bowel manage‑
ment, which can include treatments such as diet and bowel 
habit advice, medication, disposable pads and anal plugs, 
muscle/bowel training, biofeedback and electrostimulation, 
and digital stimulation and manual evacuation. It was noted 
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that the type of treatment is dependent on personal prefer‑
ence, ability and carer support.
3.4  Outcomes
The following outcomes were included in the scope: sever‑
ity and frequency of incontinence, severity of constipation, 
quality of life, length and frequency of irrigation, device‑
related adverse events, frequency of UTI, incidence of stoma 
surgery and hospitalisations, staff time (including primary 
care and community care visits), and individual length of 
use/user satisfaction.
4  Cedar’s Review of Evidence
The company provided an evidence submission to NICE 
that should be in line with the scope. This submission pre‑
sented the available clinical and cost evidence, alongside 
a de novo cost model produced by the company. Cedar’s 
assessment report aimed to provide the Medical Technolo‑
gies Advisory Committee (MTAC) with a balanced, fair, and 
independent appraisal of the evidence surrounding the use of 
Peristeen for bowel dysfunction [2]. Broadly, this involved 
(1) identifying any additional information not included in 
the manufacturer’s submission; (2) appraising the published 
clinical and cost evidence and, where necessary, present‑
ing additional data; (3) critiquing the de novo cost model 
by checking inputs, assumptions, and structural integrity; 
(4) highlighting any key issues; and (5) presenting any new 
analyses carried out.
4.1  Review of Clinical‑Effectiveness Evidence
The company submitted 10 studies consisting of 1 ran‑
domised controlled trial (RCT) of adults [3], 7 observational 
studies of adults [4–10], and 1 observational study of chil‑
dren [11], plus 1 prepublication study of adults. Cedar did 
not agree with the company’s justification for excluding all 
but one paediatric study (because they did not use validated 
scoring systems) and included all studies with relevant out‑
comes. Cedar undertook a comprehensive search and selec‑
tion process (Fig. 1) and included a further 4 observational 
studies of adults[12–15] and a further 10 observational stud‑
ies of children [16–25]. The main outcomes in the included 
studies were patient‑reported outcomes, which, due to the 
nature of the device, was appropriate. Included studies are 
listed in Table 1. 
4.1.1  Adult Studies
One reasonable‑quality RCT that included 87 adults with 
spinal cord injuries and neurogenic bowel dysfunction 
was identified [3]. This unblinded study compared transa‑
nal irrigation using Peristeen (n  =  42) with standard 
bowel care (n = 45) for 10 weeks and reported signifi‑
cant improvements in validated patient‑reported outcomes 
for bowel function. Twelve patients in the Peristeen arm 
and two standard care patients withdrew from the study. 
There was a significant improvement in a series of patient‑
reported outcome measures (PROMs)—Cleveland Clinic 
Constipation Scoring System (CCCS), St Mark’s Fecal 
Incontinence Grading System (FIGS), and Neurogenic 
Bowel Dysfunction Score (NBDS)—for the Peristeen 
group compared with standard care (Table 2).
In the observational studies of adults, which reported 
comparative data (before and after), there was an improve‑
ment in patient‑reported outcomes for bowel function 
when using Peristeen. Most of these studies used appro‑
priate standardised PROMs. Outcome measures such as 
incidence of UTIs and faecal incontinence also improved 
when using Peristeen, while outcomes related to general 
quality‑of‑life measures were less widely reported and 
changes were either not significant or were significantly 
improved in only some domains. There were considerable 
numbers of people who stopped using Peristeen, particu‑
larly in the first few months.
4.1.2  Paediatric Studies
The paediatric studies were non‑comparative, observa‑
tional, case series. Six of these observational studies were 
prospective and five were retrospective in design. The 
studies were of variable quality and used less‑consistent 
outcome measures. General findings indicated the use of 
Peristeen resulted in improvements in bowel management, 
however the evidence is weaker than for adults, partly due 
to the difficulty in obtaining valid PROM data for children.
For both adults and children, there were variable num‑
bers of people who stopped using Peristeen, particularly 
in the first few months. This was frequently because they 
disliked using the device or found it painful or ineffective.
4.1.3  Safety Outcomes
Bowel perforation is a rare but potentially serious adverse 
event that can occur with Peristeen use. A global audit 
[26] based on voluntary reporting to the company found 49 
incidents of bowel perforation, 35 of which were certainly 
caused by Peristeen. Less‑serious adverse events include 
symptoms such as abdominal pain or nausea, which may 
lead individual patients affected to seek an alternative 
management strategy.
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4.2  Review of Economic Evidence
The company identified two published economic studies [27, 
28]. The Christensen et al. [27]. model is from a societal 
perspective, however it did not match the scope and was 
therefore excluded by both Cedar and the company. The 
work of Emmanuel et al. [28]. was the basis for the de novo 
cost model which is required from the company as part of 
the evidence submission, and is critiqued in the following 
sections. The company did not update the costs in the sub‑
mitted model, but did comment on the impact the updated 
costs would have.
4.2.1  Model Structure
The submitted model was based on the work of Emmanuel 
et al. [28], a Markov model with a 6‑month cycle, compar‑
ing the use of the Peristeen transanal irrigation system with 
standard bowel care for a 30‑year‑old subject with spinal 
cord injury. The model time horizon was 37 years, with a 
discount rate of 3.5% and an NHS and social services per‑
spective. The available states in the model are management 
using Peristeen, standard bowel care, surgery, or stoma. 
Stoma is an end state in this model and patients cannot move 
from this, as shown in Fig. 2.
Key assumptions in the model are as follows.
• All patients enter the model at age 30 and survive for 37 
years. There is no death state in the model.
• The probability of ceasing to use Peristeen is assumed to 
be constant.
• Adverse events are included as hospital admissions, and 
are assumed to be split equally between gastrointesti‑
nal infections, pressure ulcers, falls or trauma, abdom‑
inal pain and UTI. Bowel perforation is not explicitly 
included.
• The model is stated as being for a patient with spinal cord 
injuries, and patients are assumed to be homogeneous.
Records idenfied through 
database searching – duplicates 
removed  
(n =227) 
Addional records idenfied 
through other sources  
(n =60) plus 62 MAUDE reports; 1 MHRA 
report; 5 clinical trials 
First screen: tle/abstract  
(n = 287) +68 (63 safety reports and 5 clinical 
trials) 
Records excluded  
(n = 247) + 3 clinical trials 
Second screen: assessed 
for eligibility at full-text 
(n = 40) 
Full-text arcles 
excluded  
(n = 14) 
Publicaons 
included in clinical 
evaluaon 
(n = 24 full text) 
Publicaons 
included in 
economic 
evaluaon  
(n = 2) 
Included: safety 
reports (n=63) & 
ongoing studies 
(n=2) 
Fig. 1  Cedar’s study selection process. MHRA Medicines and Healthcare products Regulatory Agency, MAUDE manufacturer and user facility 
device experience
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• Transition probabilities and variables are constant over 
time for all patients. Many variables are likely to change 
with age for all patients, and will also change over time 
for patients with progressive diseases such as multiple 
sclerosis.
• Transition probabilities for patients who start using Peri‑
steen and then revert to standard bowel care are stated in 
the submission as being the same as probabilities in the 
standard bowel care arm.
4.2.2  Data Sources for Outcomes and Resources
The model uses audit data for 227 patients from three UK 
hospitals as the main source of clinical and resource data. 
Data for standard bowel care are taken from the baseline 
questionnaires for patients, except for the number of patients 
progressing to stoma, which is taken from the retrospective 
data of 157 patients prior to the introduction of Peristeen. 
Limited information on the audit is published [8, 28], but 
an extract of some information was shared with Cedar by 
the company. The audit appears to have an appropriate NHS 
setting, with suitable patient pathways, and an appropriate, if 
heterogeneous, population. However, Cedar were unable to 
reconcile differences in the data from the available sources, 
and had insufficient information available to critique the 
audit data used in the model.
The statistical techniques used for calculating transition 
probabilities from patients enrolled at different time points, 
with different lengths of follow‑up, were not stated.
4.2.3  Data Sources for Adverse Events
Adverse events are modelled as UTIs that respond to 
treatment, and events requiring hospitalisation. The 
Table 1  Studies included by 
both the company and Cedar
a RCT and OBS paper by Christensen et al. used the same patients
ARM Anorectal malformation, FBD Functional bowel disorder, MS multiple sclerosis, SB spina bifida, SCI 
spinal cord injury, NBD neurogenic bowel dysfunction, IC idiopathic constipation, ARS anterior resec‑
tion syndrome, RCT randomised controlled trial, OBS observational, single‑arm study, DC discrete choice 
experiment, ✓ indicates included, ✘ indicates explicitly excluded
References Country Study type Population n Company Cedar
Adults
 Chan et al. [12] UK OBS Mixed 91 – ✓
 Christensen et al. [4] Europe including UK OBSa SCI 62 ✓ ✓
 Christensen et al. [3] Europe, including the UK RCT SCI 87 ✓ ✓
 Del Popolo et al. [5] Italy OBS SCI 36 ✓ ✓
 Pre‑publication study provided as ‘academic in confidence’ ✓ ✓
 Hamonet‑Torny et al. [6] France OBS NBD 16 ✓ ✓
 Kim et al. [13] South Korea OBS SCI 52 – ✓
 Loftus et al. [7] Ireland OBS NBD 11 ✓ ✓
 Nafees et al. [14] UK DC Mixed 129 ✓
 Passananti et al. [8] UK OBS MS 49 ✓ ✓
 Preziosi et al. [9] UK OBS MS 30 ✓ ✓
 Rosen et al. [10] Austria
Switzerland
OBS ARS 14 ✓ ✓
 Whitehouse et al. [15] UK OBS FBD 113 – ✓
Children
 Alenezi et al. [16] Saudi Arabia OBS NBD 18 ✘ ✓
 Ausili et al. [17] Italy OBS SB 60 ✘ ✓
 Choi et al. [32] South Korea OBS SB 44 ✘ ✘
 Corbett et al. [18] UK OBS Mixed 24 ✘ ✓
 Kelly et al. [19] USA OBS NBD 24 ✘ ✓
 King et al. [20] Australia OBS SB 20 ✘ ✓
 Koppen et al. [21] Netherlands OBS IC 67 ✘ ✓
 Lopez Pereira et al. [22] Spain OBS SB 40 ✘ ✓
 Marzheuser et al. [23] Germany OBS ARM 40 – ✓
 Midrio et al. [11] Italy OBS Mixed 83 ✓ ✓
 Nasher et al. [24] UK OBS IC 13 ✘ ✓
 Pacilli et al. [25] UK OBS Mixed 23 ✘ ✓
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hospitalisations are split equally between abdominal pain, 
gastrointestinal infection, pressure ulcers, falls and trauma, 
and UTIs. The assumption of an equal split is not justified 
and is likely to overestimate treatment for pressure ulcers, 
which can be very costly.
4.2.4  Errors
Cedar identified several errors in the model, the most 
important of which were all related to people in the Peri‑
steen arm who returned to using standard care. The main 
errors for these people returning to standard care were:
• the cost of a health care professional’s time was not 
included;
• the cost of standard bowel care‑related adverse events 
was not included;
• there was a lower use of consumables assumed, com‑
pared with people in the model who had never used 
Peristeen;
• a reduced probability of moving to surgery or stoma for 
people in the model receiving standard bowel care who 
had previously received Peristeen.
Cedar considered all these points to be modelling errors 
as they did not reflect the intended model function as 
described in the company submission. No evidence was 
submitted to suggest that people who used Peristeen and 
then changed back to standard care would have any dif‑
ferent resource requirement or outcomes compared with 
those who had never used Peristeen. Once these errors 
were corrected, the cost saving due to the use of Peristeen 
was reduced from £21,768 to £7829.
4.2.5  Changes Made by Cedar
The change made by Cedar that had the largest impact 
was to change the cost of a pressure ulcer from £24,214 
(Touche Ross [29], inflated) to £15,134 (Dealy [30], 
inflated). In addition, Cedar changed the cost of a UTI 
from £167.77 per episode to £52.57 (Berningham [31], 
inflated) in line with the costs listed in the original study 
referenced.
In order to reflect the high number of people ceasing to 
use Peristeen at an early stage, Cedar introduced a variable 
transition probability. Due to the limited data available, 
this was set as three different fixed values to empirically 
recreate the reported dropout rate. Background mortality 
was also added due to the long time horizon for this model.
The combined impact of these changes further reduced 
the cost saving to £3176, as shown in Table 3.
4.2.6  One‑Way Sensitivity Analysis
Cedar added frequency of use to the one‑way sensitivity 
analysis and carried out additional sensitivity analysis.
The model is very sensitive to the frequency of use 
and also sensitive to pressure ulcer treatment and faecal 
incontinence, and there is uncertainty about each of these 
variables. There is limited clinical evidence around the 
frequency of use and for an improvement in faecal incon‑
tinence. Furthermore, there is no direct clinical evidence 
Fig. 2  Markov model structure
Standard 
bowel care
Peristeen
Surgery 
Stoma
Standard 
bowel care
Surgery
Stoma
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linking the use of Peristeen to a reduction in pressure 
ulcers.
4.2.7  Key Drivers
A key driver in the model is the frequency of use, due to the 
need for a new catheter at each use. The average frequency 
is likely to be correctly modelled every other day, however 
the actual use for each patient may vary from daily to weekly 
depending on their preferences and circumstances.
The cost saving identified in Cedar’s corrected model in 
the Peristeen arm is largely due to reduced time for health 
care professional visits and carer time; reduced incidence 
of faecal incontinence (requiring fewer incontinence pads); 
and reduced incidence of UTIs and fewer hospitalisations.
5  National NICE Guidance
5.1  Preliminary Guidance
The evidence submitted by the company and Cedar’s report 
were presented to the MTAC, who produced the following 
draft recommendations:
The case for adopting Peristeen for managing neurogenic 
bowel dysfunction in adults is supported by the evidence. 
Peristeen can reduce the severity of constipation and incon‑
tinence, improve bowel‑related quality of life, and promote 
dignity and independence.
Peristeen may not be suitable for all people with neuro‑
genic bowel dysfunction and can be difficult to use. It may 
take several weeks before a person is comfortable using it 
themselves, and some people may choose to stop using it. 
Peristeen is therefore most effective when it is offered with 
specialist training for users, carers and NHS staff, along with 
structured patient support.
Cost modelling for Peristeen is associated with significant 
uncertainties, but it is likely that, overall, Peristeen provides 
additional clinical benefits without costing more than stand‑
ard bowel care.
5.2  Consultation Response
During the consultation period, NICE received 43 consulta‑
tion comments from 18 consultees (9 NHS professionals, 1 
private sector healthcare professional, 1 professional society, 
1 patient group and 6 manufacturers). The comments related 
to Peristeen use in children, functional bowel disorders, user 
experience, other transanal irrigation devices, frequency of 
use, cost and adverse events. New information was submit‑
ted from centres using Peristeen in children and in people of 
all ages with functional bowel disease. This information was 
reviewed by Cedar and presented to the committee. Because 
of this, the committee broadened the recommendations to 
include people with bowel dysfunction of any age.
6  Key Challenges and Learning Points
The Peristeen transanal irrigation system can be used suc‑
cessfully by a wide range of people whose bowel dysfunc‑
tion may have different causes and symptoms. This leads to a 
very broad scope, and the studies that inform the clinical evi‑
dence have diverse populations and outcomes. This breadth 
and diversity mean that combining the clinical evidence 
presents particular challenges. In addition, the outcomes 
Table 3  Impact on the incremental cost of additional work by Cedar
SBC standard bowel care, HCP healthcare professional, UTI urinary tract infection
Model version Incremental 
cost (over 37 
years)
Base‑case submitted by the company − £21,768
Changes 1–8: correction of errors − £7829
 Patients in the Peristeen arm returning to SBC have full costs, including appropriate medication, HCP time and adverse 
events
 Carer time in both arms is corrected
 Transition probability for all patients receiving SBC is standardised
Changes 9–10: Cedar‑suggested refinements − £6976
 9. Reduced number of Peristeen users in the first year, using variable transition probability
 10. Background mortality added
 11. Pressure ulcer cost changed to £15,134.84 − £3574
 12. UTI cost changed to £52.57 − £3175
Final Cedar base‑case with all corrections and refinements − £3175
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most important to the people who use Peristeen may not be 
the outcomes that are most easily captured and reported in 
clinical studies.
The economic evaluation aspect presented significant 
challenges due to the lack of transparency in the data 
used for clinical and resource inputs, and the significant 
structural errors contained in the model. The focus of the 
sensitivity analysis on costs rather than resource use, and 
the omission of key factors, such as frequency of use, was 
potentially misleading.
7  Conclusions
The Peristeen transanal irrigation system received a posi‑
tive recommendation from NICE and should be consid‑
ered as an option for people requiring additional treatment 
strategies to manage bowel dysfunction. Published evi‑
dence showed that the Peristeen transanal irrigation sys‑
tem improved patient‑reported outcomes in those patients 
who continued to use it. The evidence is more robust for 
the adult population, partially due to the availability of 
appropriate validated outcome measures. Consultation 
responses reported the successful use of Peristeen in chil‑
dren in the UK. The submitted economic evidence was 
based on audit data that were not available for scrutiny, 
and the model contained several errors. Despite the uncer‑
tainty that remains in the model, it is likely that use of 
the Peristeen transanal irrigation system will not cost any 
more than standard care.
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